TSTL.L

Tristel Plc
Tristel PLC - Exercise of Share Options and Total Voting Rights
19th September 2024, 12:13
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9183E
Tristel PLC
19 September 2024
 

Tristel plc

("Tristel" or the "Company")

 

Exercise of Share Options and Total Voting Rights

               

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 35,100 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.

               

Application has been made to the London Stock Exchange for the 35,100 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 24 September 2024.

 

Total Voting Rights

 

After Admission, the total number of Ordinary Shares in issue will be 47,650,093 and the total number of voting rights will therefore be 47,650,093. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information please contact:     

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer




Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Charlotte Edgar

Mob: 07884 664 686



Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance)


Sunila de Silva (ECM)


 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOELLMTTMTBBBTI]]>
TwitterFacebookLinkedIn